Salbutamol Research Paper
Abstract
The scope of this paper focuses on Salbutamol as a drug and the mechanisms behind;
1) The drug function.
2) Development of drug resistance.
3) The clinical features of drug resistant individuals.
4) How to diagnose them.
5) Management of these patients.
Salbutamol resistance
Salbutamol is a beta 2 adrenergic receptor agonist that is short acting and used in the management of conditions that cause bronchospasms/bronchoconstriction. These conditions mainly include asthma and chronic obstructive pulmonary disease. Its systemic name is (RS)-4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl) phenol. It has a half life of 1.6 hours, metabolized in the liver and exclusively excreted by the kidneys (1). …show more content…
Recovery, after therapy, is prolonged or absent even after maximum administration of effective dose. The most significant clinical feature appears in the deterioration of asthma and the subsequent exacerbation of the symptoms. Drug resistant asthma presents with (23);
• Worsening …show more content…
Hopkins, S. J., and Jennifer C. Kelly. Drugs and pharmacology for nurses . 13th ed. Edinburgh: Churchill Livingstone, 1999. Print.
13. Huxtable, Ryan J.. Taurine 2: basic and clinical aspects. New York: Plenum Press, 1996. Print.
14. Koren, Gideon. Medication safety in pregnancy and breastfeeding . New York: McGraw-Hill, Health Professions Division, 2007. Print.
15. Maddison, Jill E., Stephen W. Page, and David Church. Small animal clinical pharmacology . 2nd ed. Edinburgh: Saunders/Elsevier, 2008. Print.
16. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries.. Geneva: Dept. of Child and Adolescent Health and Development, World Health Organization :, 2000. Print.
17. Mehta, Dinesh K., Rachel S. M. Ryan, and H. V. Hogerzeil. WHO model formulary, 2004 . Geneva: World Health Organization, 2004. Print.
18. Milne, George W. A.. Gardner 's commercially important chemicals: synonyms, trade names, and properties. Hoboken, N.J.: Wiley-Interscience, 2005. Print.
19. Neonatal formulary 5 . 5th ed. Malden, Mass.: Blackwell Pub., 2007. Print.
20. Page, C. P., and Peter J. Barnes. Pharmacology and therapeutics of asthma and COPD . Berlin: Springer, 2004.
The scope of this paper focuses on Salbutamol as a drug and the mechanisms behind;
1) The drug function.
2) Development of drug resistance.
3) The clinical features of drug resistant individuals.
4) How to diagnose them.
5) Management of these patients.
Salbutamol resistance
Salbutamol is a beta 2 adrenergic receptor agonist that is short acting and used in the management of conditions that cause bronchospasms/bronchoconstriction. These conditions mainly include asthma and chronic obstructive pulmonary disease. Its systemic name is (RS)-4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl) phenol. It has a half life of 1.6 hours, metabolized in the liver and exclusively excreted by the kidneys (1). …show more content…
Recovery, after therapy, is prolonged or absent even after maximum administration of effective dose. The most significant clinical feature appears in the deterioration of asthma and the subsequent exacerbation of the symptoms. Drug resistant asthma presents with (23);
• Worsening …show more content…
Hopkins, S. J., and Jennifer C. Kelly. Drugs and pharmacology for nurses . 13th ed. Edinburgh: Churchill Livingstone, 1999. Print.
13. Huxtable, Ryan J.. Taurine 2: basic and clinical aspects. New York: Plenum Press, 1996. Print.
14. Koren, Gideon. Medication safety in pregnancy and breastfeeding . New York: McGraw-Hill, Health Professions Division, 2007. Print.
15. Maddison, Jill E., Stephen W. Page, and David Church. Small animal clinical pharmacology . 2nd ed. Edinburgh: Saunders/Elsevier, 2008. Print.
16. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries.. Geneva: Dept. of Child and Adolescent Health and Development, World Health Organization :, 2000. Print.
17. Mehta, Dinesh K., Rachel S. M. Ryan, and H. V. Hogerzeil. WHO model formulary, 2004 . Geneva: World Health Organization, 2004. Print.
18. Milne, George W. A.. Gardner 's commercially important chemicals: synonyms, trade names, and properties. Hoboken, N.J.: Wiley-Interscience, 2005. Print.
19. Neonatal formulary 5 . 5th ed. Malden, Mass.: Blackwell Pub., 2007. Print.
20. Page, C. P., and Peter J. Barnes. Pharmacology and therapeutics of asthma and COPD . Berlin: Springer, 2004.